Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

The Research Foundation Suny

Neither a doctor nor a teaching hospital

Research payments

$4,693,671

338 payments

Through program year 2025, The Research Foundation Suny is reported as receiving $4,693,671 in research payments, across 338 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $426,055 83
2024 Research $125,177 17
2023 Research $163,631 55
2022 Research $2,865,822 136
2021 Research $1,094,764 41
2020 Research $3,235 1
2019 Research $14,987 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $3,955,017 144 payments
  2. United Therapeutics Corporation $130,635 36 payments
  3. Rhythm Pharmaceuticals, Inc. $129,101 65 payments
  4. Horizon Therapeutics plc $93,270 2 payments
  5. Syndax Pharmaceuticals, Inc. $75,543 5 payments
  6. ViiV Healthcare Company $74,571 29 payments
  7. GlaxoSmithKline, LLC. $65,936 7 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $61,675 15 payments
  9. F. Hoffmann-La Roche AG $29,391 7 payments
  10. Hoffmann-La Roche Limited $23,951 11 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $3,391,367 79 payments
  2. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age $287,005 15 payments
  3. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $241,245 34 payments
  4. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $82,172 23 payments
  5. A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity Ofsndx-5613In Combination With Intensive Chemotherapy in Participants With Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-Specific Methyltransferase 2A (Kmt2a/Mll), Nucleophosmin 1 (Npm1), and Nucleoporin 98 (Nup98) Genes $75,543 5 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy and Safety of Daxdilimab in Adult Participants With Active Proliferative Lupus Nephritis $58,527 1 payment
  7. A Phase 1/2, Randomized, Dose-Finding/Dose-Confirmation Study to Evalu $44,686 1 payment
  8. A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) $44,664 12 payments
  9. Rm-493-022 $43,636 11 payments
  10. Phi Sad Study of Mosun in Patients With Sle $42,701 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record